This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Axsome Therapeutics Presents Sleep Data
Tech data presentation

Axsome Therapeutics Presents Sleep Data

Analysis based on 6 articles · First reported Jun 15, 2026 · Last updated Jun 15, 2026

Sentiment
20
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market may react positively to Axsome Therapeutics' presentations of new data on its sleep medicine portfolio, as it indicates continued development and potential for future product advancements. This could lead to increased investor confidence in Axsome Therapeutics.

biotechnology pharmaceuticals
Event Summary

Axsome Therapeutics announced the presentation of new data on its product candidates, AXS-12 and solriamfetol, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies. The presentations include cognitive and functional outcomes from the Phase 3 ENCORE Trial of AXS-12 in narcolepsy with cataplexy, a post-hoc analysis of solriamfetol for excessive daytime sleepiness in narcolepsy and OSA, and a subgroup analysis from the CRESCENDO Survey on symptom burden and quality of life in narcolepsy patients with residual cataplexy. These presentations highlight Axsome Therapeutics' ongoing research and development in central nervous system disorders.

Entities Involved
stock
Axsome Therapeutics
Axsome Therapeutics announced new data presentations for its sleep medicine portfolio, which could positively impact its product development and market position in CNS disorders.
Importance 100.0 Sentiment 20.0
ngo
Associated Professional Sleep Societies
The Associated Professional Sleep Societies is hosting SLEEP 2026, where Axsome Therapeutics is presenting its new data.
Importance 30.0 Sentiment 0.0
per
Bruce Corser
Bruce Corser is the lead author for one of the presentations on AXS-12 in narcolepsy with cataplexy.
Importance 20.0 Sentiment 0.0
per
Ellen Wertmer
Ellen Wertmer is the lead author for a presentation on solriamfetol for excessive daytime sleepiness.
Importance 20.0 Sentiment 0.0
per
Michael Thorpy
Michael Thorpy is the lead author for a presentation on symptom burden and quality of life in narcolepsy patients.
Importance 20.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
cnt
United States
Importance 0.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.